This article was originally published in The Rose Sheet
Executive SummaryWilliam Slikker, Jr., PhD, is appointed acting director of FDA's National Center for Toxicological Research, replacing Dan Casciano, PhD, who is moving to the private sector after serving in the role for more than six years, FDA announces Jan. 3. Slikker most recently worked as NCTR's deputy center director for research and is a "recognized leader in the field of toxicology, an accomplished scientist and educator, and a strong champion of NCTR's research program," agency notes...
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.